ALKS Q4 2018 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena

ALKSAlkermes plc

$5B

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$316M+14.7% YoY

Gross Profit

$267M84.4% margin

Operating Income

$20,0000.0% margin

Net Income

-$10M-3.1% margin

EPS (Diluted)

$-0.06

QoQ Revenue Growth

+27.0%

Cash Flow

Operating Cash Flow

$61M

Free Cash Flow

$43M

Stock-Based Comp.

$29M

Balance Sheet

Total Assets

$1.8B

Total Liabilities

$654M

Stockholders' Equity

$1.2B

Cash & Equivalents

$267M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$316M	$275M	+14.7%
Gross Profit	$267M	$237M	+12.6%
Operating Income	$20,000	$6M	-99.7%
Net Income	-$10M	-$10M	+0.8%

Revenue Segments

Vivitrol

$84M46%

Aristada

$49M27%

License

$48M26%

Research And Development

$2M1%

Clinical Supply

$200,0000%